MangoRx Reports 1,685% Increase in Shareholders' Equity From December 31, 2023, to $13.8MM, and 56% Increase in Year-Over-Year Revenue for First Half of 2024GlobeNewsWire • 08/15/24
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and TirzepatideGlobeNewsWire • 08/09/24
MangoRx Receives Request for Proposal (RFP) From ISFLST for New Male Enhancement Product Exclusive for the Asian MarketAccesswire • 08/08/24
MangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention TechnologyGlobeNewsWire • 07/24/24
MangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via SurescriptsGlobeNewsWire • 07/16/24
MangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation DepartmentGlobeNewsWire • 07/12/24
MangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging MarketsGlobeNewsWire • 07/11/24
MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care TechnologyGlobeNewsWire • 06/06/24
MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont TechnologiesGlobeNewsWire • 06/04/24
Mangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American MarketsGlobeNewsWire • 05/28/24
MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing EffortsGlobeNewsWire • 05/23/24
MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 MedicationsGlobeNewsWire • 05/21/24
MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market PenetrationGlobeNewsWire • 05/16/24
Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq's Minimum Stockholders' Equity RequirementGlobeNewsWire • 05/02/24
Mangoceuticals Subsidiary, MangoRx Mexico, Executes Technical Agreement with Mexican Pharmaceutical Manufacturer for Initial Development and Production of its Mango Erectile Dysfunction (ED) ProductsGlobeNewsWire • 04/12/24
MangoRx Officially Launches ‘PRIME' by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) TreatmentGlobeNewsWire • 03/12/24
MangoRx Launches Direct-To-Clinics Sales Division to Drive and Fuel Customer Acquisition and Revenue GrowthGlobeNewsWire • 02/20/24
MANGORX TO OFFER THE BIG GAME'S LOSING TEAM A FREE ONE YEAR SUPPLY OF ITS ED PRODUCT, MANGO, TO HELP RAISEGlobeNewsWire • 02/06/24
MangoRx Accepting Pre Orders for its “PRIME”, by MangoRx, Powered by Kyzatrex®️ FDA Approved Oral Testosterone Replacement Therapy (TRT) ProductGlobeNewsWire • 02/05/24
MangoRx's Brand and Products to be Featured by Barstool Sports in Week of Programming Around the Biggest Sports Event of the Year on February 11GlobeNewsWire • 01/19/24